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In this study we investigated the signaling pathways triggered by Tat in human monocyte to induce TNF-. In monocytes,
the calcium, the PKA, and the PKC pathways are highly implicated in the expression of cytokine genes. Thus, these three
major signaling pathways were investigated. Our data show that (i) PKC and calcium pathways are required for TNF-
production, whereas the PKA pathway seems to be not involved; (ii) downstream from PKC, activation of NFB is essential
while ERK1/2 MAP kinases, even though activated by Tat, are not directly involved in the pathway signaling leading to TNF-INTRODUCTION
HIV-1 infection is associated with two major disorders:
immunological dysfunctions since the asymptomatic
stage and CD4 T cell depletion at a late stage of
infection and during advancement to AIDS (Fauci, 1988).
Several viral factors including gp120, gp41, Nef, and Tat
have been reported as pathogenic factors by acting at
different levels (Fauci, 1996). These viral proteins lead to
enhanced viral replication, activation of quiescent CD4
cells, induction of apoptosis, impairment of natural and
specific immune responses, and induction of an imbal-
ance of the immunoregulation of cytokines produced
(Rosenberg and Fauci, 1990). In fact, in HIV-infected
patients, high levels of TNF- have been observed in
sera, brain, and in vitro in supernatants of monocytes,
PBMC, and alveolar macrophages from AIDS patients
(Wright et al., 1988). This proinflammatory cytokine is
implicated in at least two essential functions. First, in the
stimulation of HIV-1 replication in chronically infected
cells, and second, in the neurological disorders associ-
ated with toxic effects on neurons, oligodendrocytes, and
astrocytes (Wright et al., 1988). Since Tat has been re-
ported to induce TNF- (Chen et al., 1997), in the present
study, we analyzed the mechanisms involved in signal
transduction leading to this production.
Tat, a 14-kDa protein containing 86 to 101 amino acids
encoded by two exons, is known for its transactivating
activity; it is essential for efficient HIV-1 viral replication.
Tat also participates in the pathogenesis of HIV-1 infec-
tion by its capacity to interact with different cell types and
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174alter the complex network of cytokines involved in the
regulation of the immune response (Rubartelli et al.,
1998). HIV-Tat have been detected in sera of HIV-infected
patients at the nanomolar level (Westendorp et al., 1995;
Xiao et al., 2000), a value which may be underestimated
since Tat can be trapped by its potential receptors, and
particularly the heparan sulfates, molecules largely ex-
pressed on cell surfaces (Rubartelli et al., 1998). Further-
more this concentration would be higher near to produc-
tively infected cells in lymph nodes. Indeed, Tat is se-
creted by infected cells (Ensoli et al., 1993) and can act
on other cells, whether or not they are infected (Mann
and Frankel, 1991).
The aim of the present work was to determine the
intracellular signal transduction mechanisms involved in
the induction of TNF- by Tat in human monocytes.
RESULTS
Tat induces the production of TNF- by human
monocytes
The stimulation of human monocytes by increasing
concentrations of Tat protein leads to a dose-dependent
production of TNF- (Fig. 1A). The specific effect of Tat
was demonstrated by the capacity of anti-Tat monoclonal
antibodies to inhibit TNF- production and similarly, by
the inability of oxidized Tat (inactivated form for transac-
tivation but still immunogen) to induce TNF- (Fig. 1A). To
determine whether TNF- is produced by monocytes or
by other cell types, the nonadherent cell fraction was
subjected to successive adherence steps to deplete it of
monocytes and was stimulated by Tat protein for 24 h.
PBMCs thus depleted in monocytes could not produce
TNF- after Tat stimulation (Fig. 1B). In contrast, as ex-production. © 2002 Elsevier Science (USA)
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These results suggest that TNF- production observed
was due to monocytes. Since Tat protein contains sev-
eral active regions including the cysteine-rich domain
(amino acids 20–38), the basic region (amino acids 47–
57), and also the RGD tripeptide (amino acids 78–80), we
try to identify the region involved in this TNF- induction.
Stimulation of monocytes by Tat deletion mutants GST-
Tat1-72 and GST-Tat1-55 induces a similar amount of
TNF- as the wild-type GST-Tat1-101 (Fig. 2A). In con-
trast, mutants GST-Tat20-72 and GST-Tat30-72 cannot
stimulate TNF- production by monocytes. These results
show that the N-terminal region (1–55) contains the ac-
tive domain (Fig. 2A). To determine whether Tat protein
interacts with the membrane or must enter the monocyte
to induce TNF- production, Tat protein was immobilized
in culture wells. Stimulation of monocytes by increasing
concentrations of immobilized Tat led to a dose-depen-
dent production of TNF-. Thus, immobilized Tat protein
is still able to induce TNF-, suggesting that a membrane
interaction is sufficient to initiate this induction (Fig. 2B).
Tat-mediated TNF- production by monocytes
depends on the calcium and protein kinase C
pathways, but is independent of PKA
The signal transduction pathway triggered by Tat to
induce TNF- production by monocytes was investi-
gated. Three signaling pathways predominant in mono-
cytes, known for inducing the expression of cytokine
genes, were studied: the protein kinase C (PKC), the
calcium, and the protein kinase A (PKA) pathways
(Fraser et al., 1993).
Initially, we determined whether phospholipase C
(PLC), the common starting point of the PKC and the
calcium pathways, was involved in this induction. Prein-
cubation of monocytes with increasing concentrations of
U 73122, a PLC inhibitor, inhibits in a dose-dependent
manner Tat-induced TNF-. This inhibition reached 62%
when the inhibitor was used at 10 M (Fig. 2C). Follow-
ing its activation, PLC cleaves phosphatidyl inositol bi-
phosphate (PIP2) to inositol-1,4,5-triphosphate (IP3), re-
sponsible for the release of intracellular stocks of cal-
cium, and to diacylglycerol (DAG) responsible for the
activation of protein kinase C. Therefore, we investigated
if the pathways downstream from PLC were involved in
Tat-mediated TNF- production.
Since Tat protein can induce a mobilization of intra-
cellular calcium in human monocytes (Albini et al., 1996
and data not shown), we thus analyzed initially the pos-
sible involvement of the calcium pathway. Initiated by the
presence of IP3 responsible for the mobilization of intra-
cellular calcium, this pathway activates calcineurin, a
phosphatase that in turn activates transcription factor
NF-AT by dephosphorylation. In this dephosphorylated
form, NF-AT is translocated into the nucleus, where it can
bind to a specific site on cell promoter genes, including
those coding for cytokines (Rao, 1994). The preincuba-
tion of monocytes with BAPTA/AM, an intracellular cal-
cium chelator, inhibited Tat-induced TNF- production by
56%, suggesting the involvement of this pathway (Fig.
3A). In agreement with this result, cyclosporin A, an
inhibitor of calcineurin that acts by preventing the de-
phosphorylation of NF-AT that thus remains sequestered
in the cytoplasm, inhibits the induction of TNF- (47%).
Furthermore, when monocytes were incubated in a cal-
cium-free medium, Tat could no longer induce TNF-
production (Fig. 3B). Supplementing the medium with
calcium chloride restored TNF- induction by Tat. Alto-
FIG. 1. Tat specifically induces TNF- production by human mono-
cytes. (A) Monocytes (106) were incubated with Tat (1, 10, or 100 nM) for
24 h; culture supernatants were recovered and the presence of TNF-
was determined by ELISA. To study the specificity of Tat effect, mono-
cytes were stimulated with Tat (10 nM) preincubated for 1 h with a
mixture of three monoclonal anti-Tat antibodies [mouse monoclonal
antibodies directed against regions 1–15, 46–60, and 74–86 of HIV-TatLAI
were obtained from the “Agence Nationale de la Recherche sur le SIDA”
(Paris, France)], or with oxidized Tat at 100 nM for 24 h. (B) Peripheral
blood mononuclear cells were depleted of monocytes by three succes-
sive adherence steps in 24-well plates. After each adherence step,
cells remaining in suspension (106) were incubated with Tat at 10 or 100
nM. Culture supernatants were recovered and the presence of TNF-
was determined by ELISA. The results are expressed in picograms per
milliliter. The values are the means SD of three experiments from one
donor. Similar results were obtained with cells from the blood of three
different donors.
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gether these results show that Tat-mediated TNF- pro-
duction depends on the calcium pathway.
In parallel, involvement of the PKA pathway was inves-
tigated. This pathway is initiated following the activation
of adenylate cyclase by a receptor in association with G
protein, leading to an increase in the cellular cAMP
concentration. Mobilization of cAMP leads to the activa-
tion of PKA, a kinase that can phosphorylate and thus
recruit transcription factor CREB (Meinkoth et al., 1993).
The use of increasing active concentrations of H89, a
PKA inhibitor, had no effect on the Tat-mediated produc-
tion of TNF- (Fig. 3C). These results suggest that the
PKA pathway does not play an essential role in the
induction of TNF-.
Finally, the involvement of PKC in TNF- production
was analyzed, using RO31-8220, a specific inhibitor of
PKC. When monocytes were pretreated with RO31-8220
(2.5 and 5 M), Tat-induced TNF- production was
strongly inhibited, reaching 62% for 5 M of inhibitor (Fig.
3D). These results indicate the involvement of PKC in this
induction.
Downstream from PKC, ERK1/2 MAP kinases, even
though activated by Tat, are not required, while
activation of NFB is essential
Therefore, the pathways recruited downstream from
PKC were investigated. To this aim, the involvement of
two known PKC substrates was studied: the MAP ki-
nases ERK1/2 pathway and transcription factor NFkB.
Mitogen-activated protein (MAP) kinase p42 and p44,
also called ERK 1 and 2, can be activated by PKC. This
FIG. 2. Tat induces TNF- by acting at the membrane level: involvement of PLC. (A) Monocytes (106) were incubated with wild-type GST-Tat1-101
(1, 10 nM) or with recombinant mutants GST-Tat1-72, GST-Tat1-55, GST-Tat20-72, or GST-Tat30-72 (1, 10 nM) or as a negative control with GST for 24 h.
(B) Tat was immobilized in wells by incubation for 2 h at 37°C. After two washes to eliminate nonfixed Tat, monocytes (106) were added and cultured
for 24 h with different concentrations of Tat (5, 50, or 500 nM). The results are expressed in picograms per milliliter. (C) Monocytes (106) were
pretreated or not with U73 122 (5, 10 M) for 30 min. Tat (10 nM) was then added for 24 h. Culture supernatants were recovered and the presence
of TNF- was determined by ELISA. The results are expressed in picograms per milliliter. The values are the means  SD of three experiments.
Similar results were obtained with cells from the blood of three different donors.
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activation occurs after their phosphorylation by a cas-
cade of kinases (Raf/MEK/ERK) initiated by PKC (Ueda et
al., 1996). Once phosphorylated, ERK1/2 can activate
transcription factors that could bind to the promoter of
cytokine genes. Since 30 min of Tat stimulation, a dose-
dependent phosphorylation of ERK1/2 was observed,
while no phosphorylation was detected in unstimulated
cells (Fig. 4A). Thus Tat protein activates ERK1/2. How-
ever, pretreating monocytes with PD98 059, an ERK1/2
inhibitor used at active concentrations, had no effect on
Tat-mediated TNF- production (Fig. 4A), suggesting that
ERK1/2 are not involved in this induction.
In these conditions, Tat can activate another potential
substrate of PKC: transcription factor NFkB (Baeuerle
and Baltimore, 1996). In nonactivated cells, NFkB is se-
questered in the cytoplasm by the inhibiting protein IkB
that masks its nuclear localization sequence. To become
active, NFkB must be translocated into the nucleus; this
process first involves the phosphorylation of IkB, fol-
lowed by its degradation in the proteasome pathway. By
using EMSA, we show that Tat activates the nuclear
translocation of NFkB in human monocytes (Fig. 4B).
Furthermore, the N-terminal domain 1–55 that is respon-
sible for TNF- induction (Fig. 2A) also activate NFkB,
whereas GST-Tat20-72, a mutant unable to induce TNF-
(Fig. 2A), remains unable to activate NFkB (Fig. 4B, left).
Thus there is a correlation between the induction of
TNF- by Tat and the activation of NFkB. The involvement
of NFkB was further characterized by using TLCK, a
serine protease inhibitor that acts by inhibiting the deg-
radation of IkB, thereby sequestering NFkB in the cyto-
plasm. Pretreating monocytes with TLCK led to a dose-
dependent inhibition of TNF- production that became
total at the inhibitor concentration of 200 M (Fig. 4B,
right). Altogether, these results strongly suggest that the
PKC is involved in this induction, recruiting downstream
the transcription factor NFkB whose activation appears
to be crucial to induce TNF- production.
DISCUSSION
In this study, we have shown that Tat protein of HIV-1
acts at the extracellular level to specifically induce the
production of TNF- by human peripheral blood mono-
FIG. 3. Calcium and PKC pathways are involved in Tat-mediated TNF- induction, whereas the PKA pathway seems to be not necessary. Monocytes
were pretreated or not for 30 min with CsA (0.1 or 1 g/ml) or BAPTA/AM (10 or 20 M) (A) or with the PKC inhibitor RO 31-8220 (2.5 and 5 M) (C)
or with the PKA inhibitor H89 (50 and 100 M) (D) for 30 min. Tat was then added for 24 h. In C, monocytes were incubated in a calcium-free medium
and stimulated by Tat for 24 h. In some experiments, the calcium was restored by supplementing the medium with calcium chloride (4 mM) before
Tat stimulation. Culture supernatants were recovered and the presence of TNF- was determined by ELISA. The results are expressed in picograms
per milliliter. The values are the means  SD of three experiments. Similar results were obtained with monocytes from three different donors.
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cytes. Analyses of signal transduction pathways have
shown that the calcium and the PKC pathways initiated
by PLC are involved in this induction, whereas PKA is
apparently not necessary. Downstream from PKC, the
activation of NFkB is required, while MAP kinases
ERK1/2, even though activated by Tat, are not involved.
The prior immobilization of Tat in culture wells, to
prevent its intracellular penetration, resulted in an induc-
tion of TNF- similar to that obtained with soluble Tat. It
indicates that this effect of Tat does not require its pen-
etration and probably involves an interaction with a
membrane receptor. Different regions of Tat have in fact
been implicated in interactions with various receptors:
the N-terminal region with the CD26 receptor, the tripep-
tide RGD (Arginine-Glycine-Aspartate) with integrins
v3 and 51 of dendritic cells, and the basic region
with membrane lipids and the VEGF receptor of endo-
thelial cells (Rubartelli et al., 1998). The induction of
TNF- by Tat involves the calcium pathway, as shown
using BAPTA/AM, a chelator of intracellular calcium, and
cyclosporin A, an inhibitor of calcineurin. Therefore, the
origin of mobilized calcium can be raised. Recent work
by Mayne et al. (2000) showed that Tat leads to the
mobilization of intracellular calcium from IP3-sensitive
stores in primary macrophages, calcium that should be
probably responsible for the induction of TNF-. These
results agree with the inhibition of TNF- obtained when
this pathway was inhibited with U73122, a PLC inhibitor
that cleaves PIP2 to IP3. However, in contrast to the work
by Mayne et al. on macrophages, our results show that
the production of TNF- by Tat-stimulated monocytes is
totally blocked in the absence of extracellular calcium.
On the other hand, our conclusion agrees with work of
the same group showing the involvement of extracellular
calcium in addition to the IP3-sensitive store in neurons
and astrocytes stimulated by Tat (Haughey et al., 1999).
This difference between our results and those of Mayne
et al. in the model of macrophages stimulated by Tat may
be explained by the fact that these authors used macro-
phages differentiated for 7 days from monocytes, treated
with 100 nM Tat, and also by the calcium-depletion
method involving EGTA that, despite its efficacy, could
not lead to total calcium depletion.
TNF- produced by uninfected cells would contribute
to the development of neurological diseases associated
with HIV. In addition to the immune dysfunction induced
by Tat through the induction of TNF- and IL-10, and the
inhibition of IL-12, our group has described for the first
time the neurotoxic activity of HIV-1 Tat (Sabatier et al.,
1991). The extracellular Tat released in the central ner-
vous system from infected infiltrating monocytes/macro-
phages and microglial cells could induce the toxic cyto-
kine TNF-, which can act directly on adjacent cells to
cause neurotoxicity and neurodegeneration by acting on
neurons, oligodendrocytes, and astrocytes (Talley et al.,
1995).
By inducing TNF-, Tat appears to actively contribute,
as a pathogenic and immunosuppressive factor, to dis-
ease progression. However, as reported by several stud-
ies, cellular and humoral immune responses against Tat
may control the acute phase of infection in Tat-vacci-
nated macaques and progression to AIDS in HIV-1-in-
fected humans. Taking into account the toxic and immu-
FIG. 4. Activation and recruitment of NFkB and MAP kinases ERK1/2.
(A) On the top, the activation of MAP kinase ERK1/2 by Tat was
analyzed by Western blot. Cytoplasmic protein extracts were prepared
from monocytes (2  106) treated with Tat (10 or 100 nM) or with PMA
(50 ng/ml) for 30 min. Visualization was done with an antibody recog-
nizing total ERK1/2 (ERK1/2) or only phosphorylated ERK1/2. These
results are representative from two independent experiments done on
the cells of two different donors. On the bottom, effect of PD 98 059 (PD)
at 10 or 100 M, an inhibitor of MAPK ERK1/2, on monocytes (106)
treated with 10 nM Tat. (B) Activation of NFkB was evaluated by the
electrophoretic mobility shift assay. Nuclear protein extracts of mono-
cytes treated for 16 h with wild-type GST-Tat 101, mutants GST-Tat1-55,
GST-Tat20-72, or with GST as a negative control were incubated with a
sequence containing 32P-labeled NFkB site 5-GCTGGGGACTTTC-
CAGGGAG-3. Electrophoresis was carried out at 120 V in a 5% poly-
acrylamide gel. Gel was dried and exposed overnight to a Kodak film.
The role of NFkB in Tat-induced TNF- production was evaluated by
pretreating monocytes (106) with TLCK (50 and 200 M) for 30 min
before stimulation with 10 nM of Tat.
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nosuppressive effects of Tat, the development of Tat as a
vaccine component must include only biologically inac-
tivated Tat derivatives.
MATERIALS AND METHODS
Recombinant HIV-1 Tat protein
Recombinant HIV-1 Tat protein was obtained from
“Agence Nationale de la Recherche sur le SIDA” (Paris,
France) or produced and purified as a GST-Tat fusion
protein. HIV-Tat mutants were produced as glutathione-
S-transferase (GST) fusion proteins in Escherichia coli.
The wild-type GST-Tat1-101 and Tat deleted mutants
GST-Tat1-55, GST-Tat20-72, and GST-Tat30-72 were puri-
fied as previously described (Bennasser and Bahraoui,
2002). As control, GST was purified in the same condi-
tions and used in the same experiments. All these con-
structions are LPS-free (0.3 EU/g) and biologically
active as previously described (Bennasser and Bahraoui,
2002).
In some experiments, Tat was immobilized in wells by
incubation for 2 h at 37°C. After two washes to eliminate
nonfixed Tat, monocytes (106) were added and cultured
for 24 h with different concentrations of Tat (5, 50, or 500
nM). In these conditions Tat do not enter cells as as-
sessed by an intracellular Tat-dependent transactivation
assay performed with HeLa P4 cells stably transfected
with a HIV-1 LTR-lacZ construct as previously described
(Wright et al., 1988).
Monocyte isolation
PBMC were isolated from buffy coat from healthy HIV-
negative donors in a Ficoll density gradient (Pharmacia).
The PBMC were resuspended in 60/30 complete me-
dium [60% AIM V and 30% Iscove (Gibco)] containing
penicillin (100 IU/ml), streptomycin (100 mg/ml), and 10%
fetal calf serum (FCS). PBMC were then plated at a
density of 106 cells/well in 24-well Primaria (Becton–
Dickinson) tissue culture plates. After 24 h of culture at
37°C in 5% CO2, nonadherent cells were removed, and
the remaining cells were washed twice and used as
monocytes in our assays. Adherent cells labeled with
anti-CD14 or anti-CD3 antibodies analyzed by FACS were
90% CD14 and 3% CD3.
Signal transduction experiments
Isolated monocytes were preincubated for 30 min with
various signal transduction pathway inhibitors, and HIV-1
Tat (10 nM) was added for an additional 24 h. The
following inhibitors were used: U73122, cyclosporin A,
Ro31-8220, TLCK, PD 98059, and H-89 (Calbiochem). A
putative cytotoxic effect of the different inhibitors was
tested by trypan blue dye exclusion assay and none was
found to be cytotoxic (viability was 90%) at the concen-
trations used.
TNF- detection by enzyme-linked immunosorbent
assay
TNF- production was quantified by using a two-site
sandwich enzyme-linked immunosorbent assay. MAB
617 (R&D Systems, Oxon, U.K.) monoclonal antibody (4
g/ml) was used for capture overnight at room temper-
ature. After three washes with PBS containing 0.05%
Tween 20 (wash buffer), plates were blocked by adding
300 l PBS containing 1% BSA and 5% sucrose to each
well for a minimum of 1 h. After three washes, culture
supernatants (100 l/well) were incubated for 2 h at
room temperature. Plates were then washed three times
and incubated with biotinylated anti-human TNF- poly-
clonal antibody (BAF 617), obtained from R&D Systems,
for 2 h at room temperature. After washing, the bound
biotinylated polyclonal antibody was visualized by an
additional 20 min incubation with streptavidin peroxi-
dase (Sigma, Saint Quentin Fallavier, France) diluted
1/16,000 in PBS–Tween–bovine serum albumin. After
washing, the plates were incubated with the substrate
O-phenylendiamine dihydrochloride plus H2O2 (Sigma).
The reaction was stopped by adding 50 l of H2SO4 (4 N)
to each well. Absorbance was read at 490 nm with a
wavelength correction of 600 nm. Cytokines were quan-
tified from a standard curve generated by using various
concentrations of recombinant human TNF- (R&D Sys-
tems). The limit of detection was 15 pg/ml.
Analysis of ERK1/2 activation
After incubating cells (106) in the presence or absence
of Tat or PMA for 15 or 30 min, cold Tris-buffered saline
(TBS, pH 7.8) was added, and the cells were microfuged
at 4°C for 15 s. The pellet was resuspended in 200 l of
lysis buffer [10 mM HEPES (pH 7.9), 0.1 mM EGTA, 0.1 mM
EDTA, 10 mM KCl, 1 mM DTT, and 0.5 mM PMSF]. After
15 min on ice, 7 l 10% Nonidet P-40 solution the cyto-
plasmic extracts was microfuged at 4°C for 30 s, and the
supernatants were stored at 80°C until used. Gener-
ated extracts were subjected to SDS–PAGE, and an im-
munoblotting was conducted using either rabbit poly-
clonal anti-phospho-p44/42 MAP kinase (Thr202/Tyr204)
antibody (1/1000) (New England Biolabs, Hertfordshire,
England) or rabbit anti-p44/42 MAP kinase antibody (1/
1000) (New England Biolabs). The membranes were then
visualized using a chemiluminescent substrate (Pierce,
Rockford, IL).
Electrophoretic mobility shift assay
Monocytes were stimulated with GST-Tat1-101 or Tat
mutants GST-Tat1-72 or GST-Tat1-55, or as a negative
control with GST for 16 h. Nuclear extracts were pre-
pared as previously described (Briant et al., 1998).
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Statistical analysis
The Mann & Whitney non-parametrical test was used
in this study to compare data of stimulated cells in the
absence and presence of inhibitors.
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